Ocugen is advancing two novel biologicals and a marketed drug product as a re-purposed drug under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway to treat sight threatening ocular disorders. OCU100 is a recombinant form of lens epithelium derived growth factor.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/15/16 | $6,000,000 | Series A |
EB5 Life Sciences | undisclosed |
| 11/07/24 | $30,000,000 | Credit Facility |
Avenue Capital Group | undisclosed |
